このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Humanwell Healthcare (Group)Ltd 将来の成長

Future 基準チェック /16

Humanwell Healthcare (Group)Ltd利益と収益がそれぞれ年間18.2%と8.4%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に13.5% 17.9%なると予測されています。

主要情報

18.2%

収益成長率

17.9%

EPS成長率

Pharmaceuticals 収益成長	17.5%
収益成長率	8.4%
将来の株主資本利益率	13.5%
アナリストカバレッジ	Low
最終更新日	08 Apr 2024

今後の成長に関する最新情報

Recent updates

Humanwell Healthcare (Group) Co.,Ltd.'s (SHSE:600079) Low P/E No Reason For Excitement

May 22

業績と収益の成長予測

SHSE:600079 - アナリストの将来予測と過去の財務データ ( )CNY Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	31,118	3,280	N/A	4,306	2
12/31/2025	28,866	2,958	N/A	3,011	3
12/31/2024	26,697	2,541	N/A	3,606	3
3/31/2024	24,666	1,956	428	2,306	N/A
12/31/2023	24,525	2,134	9	1,967	N/A
9/30/2023	24,194	2,028	615	2,545	N/A
6/30/2023	24,142	2,305	761	2,495	N/A
3/31/2023	23,379	2,235	344	1,959	N/A
12/31/2022	22,338	2,484	-672	2,441	N/A
9/30/2022	21,943	2,448	-970	2,225	N/A
6/30/2022	21,459	2,158	-1,059	2,140	N/A
3/31/2022	21,063	1,931	-964	2,272	N/A
12/31/2021	20,549	1,317	476	2,179	N/A
9/30/2021	20,384	1,630	326	1,816	N/A
6/30/2021	20,694	1,276	852	2,259	N/A
3/31/2021	20,465	1,313	703	1,937	N/A
12/31/2020	20,680	1,006	992	2,090	N/A
9/30/2020	20,549	710	1,128	2,024	N/A
6/30/2020	20,940	898	1,018	1,721	N/A
3/31/2020	21,119	806	1,158	1,911	N/A
12/31/2019	21,807	843	1,228	2,038	N/A
9/30/2019	21,200	-2,261	958	1,958	N/A
6/30/2019	20,317	-2,523	238	1,473	N/A
3/31/2019	19,459	-2,362	-97	1,133	N/A
12/31/2018	18,634	-2,358	-714	603	N/A
9/30/2018	18,299	778	-1,711	-256	N/A
6/30/2018	17,422	2,195	-1,638	-196	N/A
3/31/2018	16,554	2,049	-1,688	-60	N/A
12/31/2017	15,446	2,069	N/A	93	N/A
9/30/2017	14,240	2,149	N/A	193	N/A
6/30/2017	13,478	781	N/A	170	N/A
3/31/2017	12,979	881	N/A	159	N/A
12/31/2016	12,331	832	N/A	526	N/A
9/30/2016	11,898	836	N/A	597	N/A
6/30/2016	11,294	781	N/A	498	N/A
3/31/2016	10,602	668	N/A	141	N/A
12/31/2015	10,054	654	N/A	311	N/A
9/30/2015	8,941	565	N/A	96	N/A
6/30/2015	8,213	523	N/A	191	N/A
3/31/2015	7,579	494	N/A	556	N/A
12/31/2014	7,052	452	N/A	503	N/A
9/30/2014	6,754	435	N/A	887	N/A
6/30/2014	6,518	440	N/A	901	N/A
3/31/2014	6,239	425	N/A	747	N/A
12/31/2013	6,010	418	N/A	498	N/A
9/30/2013	6,062	389	N/A	203	N/A
6/30/2013	5,821	412	N/A	157	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 600079の予測収益成長率 (年間18.2% ) は貯蓄率 ( 2.9% ) を上回っています。

収益対市場: 600079の収益 ( 18.2% ) CN市場 ( 22.8% ) よりも低い成長が予測されています。

高成長収益: 600079の収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: 600079の収益 ( 8.4% ) CN市場 ( 13.9% ) よりも低い成長が予測されています。

高い収益成長: 600079の収益 ( 8.4% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 600079の自己資本利益率は、3年後には低くなると予測されています ( 13.5 %)。

Humanwell Healthcare (Group)Ltd 将来の成長

Future 基準チェック /16

主要情報

今後の成長に関する最新情報

Price target decreased to CN¥33.31

Analysts update estimates

Price target lowered to CN¥10.32

Recent updates

Dividend of CN¥0.46 announced

Humanwell Healthcare (Group) Co.,Ltd.'s (SHSE:600079) Low P/E No Reason For Excitement

First quarter 2024 earnings released: EPS: CN¥0.30 (vs CN¥0.41 in 1Q 2023)

Full year 2023 earnings: EPS exceeds analyst expectations

Humanwell Healthcare (Group) Co.,Ltd., Annual General Meeting, Apr 25, 2024

Investor sentiment improves as stock rises 17%

Humanwell Healthcare (Group) Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 29, 2024

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Second quarter 2023 earnings released: EPS: CN¥0.41 (vs CN¥0.35 in 2Q 2022)

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.42 (vs CN¥0.27 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.41 (vs CN¥0.23 in 2Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Less than half of directors are independent

Novo Holdings A/S agreed to acquire The Ritedose Corporation from AGIC Capital, Humanwell Healthcare (Group) Co.,Ltd. (SHSE:600079) and others.

Third quarter 2021 earnings released: EPS CN¥0.27 (vs CN¥0.16 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.23 (vs CN¥0.19 in 2Q 2020)

Price target decreased to CN¥33.31

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.10 in 1Q 2020)

Investor sentiment improved over the past week

New 90-day low: CN¥25.74

Investor sentiment deteriorated over the past week

New 90-day low: CN¥27.26

New 90-day low: CN¥30.20

Humanwell Healthcare (Group) Co.,Ltd. to Report Q3, 2020 Results on Oct 26, 2020

New 90-day low: CN¥30.82

Analysts update estimates

Humanwell Healthcare (Group) Co.,Ltd. (SHSE:600079) entered into a preliminary letter of intent to acquire an additional 13% stake in YiChang Humanwell Pharmaceutical Co., Ltd from Li Jie, Chen Xiaoqing, and Xu Huabin.

Price target lowered to CN¥10.32

New 90-day high - CN¥38.00

New 90-day high - CN¥36.85

Chongqing Pharmaceutical (Group) Co., Ltd. signed the Sichuan Humanwell Pharmaceutical Co., Ltd. Equity Transfer Contract to acquire 70% stake in Sichuan Humanwell Pharmaceutical Co., Ltd from Humanwell Healthcare (Group) Co.,Ltd. (SHSE:600079) for approximately CNY 360 million.

Humanwell Healthcare (Group) Co.,Ltd. to Report First Half, 2020 Results on Aug 22, 2020

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘